Resolution of the Council of Experts of May 20, 2023 "Issues of safety in the treatment of a rheumatological patient"

At the meeting of the Expert Council on May 20, the safety of treatment for patients with osteoarthritis (OA), the most common form of joint disease, was discussed. The first step in the treatment of OA should be the administration of symptomatic delayed-acting agents (SYSADOA) and nonsteroidal anti-inflammatory drugs (NSAIDs). However, given the current understanding of the pathogenesis of inflammation, as well as the fact that it is an active process involving multiple proinflammatory and pro-resolving mediators, it is reasonable to limit the cyclooxygenase-2 suppressive treatment and to include medications with multipurpose effects that contribute to the resolution of inflammation, in particular Zeel® T and Traumeel® S. Traumeel® S affects all stages of inflammation, mostly on the pro-resolving mediators synthesis, and Zeel® T affects chondrogenesis, inflammation, metabolic processes in cartilage tissue and prevents angiogenesis.

It was found that it is advisable to use Traumeel® S when it is not possible to prescribe systemic NSAIDs for pain relief. The combination of the proven therapeutic efficacy of Zeel® T and Traumeel® S with a minimal number of adverse events and the absence of interactions with other drugs allows them to be used as an independent treatment regimen for OA.

1. https://www.who.int/ru/news-room/fact-sheets/detail/musculoskeletal-conditions

2. Zotkin EG, Dydykina IS, Lila AM. Inflammatory theory of aging, age-associated diseases and osteoarthritis. Russkii meditsinskii zhurnal. 2020;(7):33-38. (In Russ.).

3. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4d32482f-b9d4-482e-b3a3-560ab062ab25

4. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=12722d14-1d5d-45d9-9d31-a6cb8eb1a969

5. Sanchez C, Hemmer K, Krommelbein N, et al. Reduction of Matrix Metallopeptidase 13 and Promotion of Chondrogenesis by Zeel T in Primary Human Osteoarthritic Chondrocytes. Front Pharmacol. 2021 May 11;12:635034. doi: 10.3389/fphar.2021.635034. eCollection 2021.

6. Tunyn H, Tunyn Н, Olavsdotter C, Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J Ethnopharmacol. 1995 Oct;48(2):61-76. doi: 10.1016/0378-8741(95)01285-1.

7. Leone S, Ottani A, Bertolini A. Dual acting anti-inflammatory drugs. Curr Top Med Chem. 2007;7(3):265-75. doi: 10.2174/156802607779941341.

8. Basini G, Santini SE, Bussolati S, Grasselli F. Sanguinarine inhibits VEGF-induced Akt phosphorylation. Ann N Y Acad Sci. 2007 Jan;1095:371-376. doi: 10.1196/annals.1397.

9. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dd923ce7-1cb5-4188-914b-541f91159b3c

10. Dydykina IS, Zotkin EG, Kovalenko PS. The contribution of bioregulation therapy to the treatment of diseases of the musculoskeletal system. Resolution on the results of the forum 01.03.2019. Consilium Medicum. 2019; 21(9):103-109. (In Russ.).

11. Basini G, Bussolati S, Santini SE, Grasselli F. Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix. Biofactors. 2007;29(1):11-8. doi: 10.1002/biof.5520290102.

12. Heine H, Andra F. The Antiinflammatory Action Mechanism of an Antihomotoxic Composite Remedy. Arz.tez.eitschriftfur Naturheilverfahren. 2002;(4):96-104.

13. Seilheimer B, Wierzchacz C, Gebhardt R. Influence of Traumeel on cultured chondrocytes and recombinant human matrix metalloproteinases: implications for chronic joint diseases. Eur J Integr Med. 2009;1(4):252-3.

14. Schmolz M. Transforming Growth Factor beta (TGF-a): eine neue Regelstrecke for antiphlogistische Therapien? Biol Med. 2000; 29(1):31-34

15. Weh L. Incubation in preparations as a means of in uencing cartilage mechanics: a mechanical study. Biological Therapy. 1990;8(4):91-93.

16. Barkin RL, Beckerman M, Blum SL, et al. Should nonsteroidal antiinflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010 Oct 1;27(10):775-89. doi: 10.2165/11539430-000000000-00000.

17. Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of non-steroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015; 9(1):4-23. (In Russ.). doi: 10.14412/1996-7012-2015-1-4-23

18. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol. 2017 Jun; 187(6):1211-1221. doi: 10.1016/j.ajpath.2017.01.018.

19. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010 Mar 19;140(6):871-82. doi: 10.1016/j.cell.2010.02.029.

20. Interdisciplinary problem of inflammation. Expert Council. Consilium Medicum. 2020; 22(9):96-101. (In Russ.).

21. St Laurent G3rd, Seilheimer B, Tackett M, et al. Deep Sequencing Transcriptome Analysis of Murine Wound Healing: Effects of a Multicomponent, Multitarget Natural Product Therapy-Tr14. Front Mol Biosci. 2017 Aug 17;4:57. doi: 10.3389/fmolb.2017.00057. eCollection 2017.

22. https://www.rmj.ru/articles/revmatologiya/Kompleksnye_bioregulyacionnye_preparaty_v_terapii_osteoartrita/

23. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=659f724e-8f5f-434c-85f5-6239cf355966

24. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cdb8f87d-ea6c-4f27-bff0-15b3d2170e70

25. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d82b8433-896f-43bb-aa78-d756a589da87

26. Gonzalez de Vega C, Speed C, Wolfarth B, Gonzalez J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract. 2013 Oct;67(10):979-89. doi: 10.1111/ijcp.12219. Epub 2013 Jul 25.

27. St Laurent G3rd, Seilheimer B, Tackett M, et al. Deep sequencing transcriptome analysis of the effect of Traumeel versus diclofenac therapeutic action in wound healing. Ann Rheum Dis. 2017;76(Suppl. 2):202

28. Sugimoto MA, Vago JP, Perretti M, Teixeira MM. Mediators of the Resolution of the Inflammatory Response. Trends Immunol. 2019 Mar;40(3):212-227. doi: 10.1016/j.it.2019.01.007. Epub 2019 Feb 13.

29. Kovalenko PS, Dydykina IS, Zhuravleva MV, Zotkin EG. From empirical results of clinical efficacy to evidence of the antiinflammatory effect of Traumel® in vitro and in vivo. Effektivnaya farmakoterapiya. 2020;16(6):16-21. (In Russ.).

30. Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017 Dec;58:1-11. doi: 10.1016/j.mam.2017.03.001. Epub 2017 Mar 3.

31. Garkavi AV, Kavalerskii GV, Terkhin SV, Meshcheryakov VA. Relief of pain syndrome — is there an alternative to NSAIDs? Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2018;(1):50-3. (In Russ.).

32. Orizola AJ, Vargas F. The efficacy of Traumeel S versus diclofenac and placebo ointment in tendinous pain in elite athletes: a randomized controlled trial. Med Sci Sports Med Exerc. 2007;39(Suppl. 5):858.

33. Bohmer D, Ambrus P. Treatment of sports injuries with Traumeel ointment: a controlled doubleblind study. Biol Ther. 1992;10: 290-300.

34. Zell J, Connert WD, Mau J, Feuerstake G. Behandlung von akuten Sprunggelenksdistorsionen: Doppelblindstudie zum Wirksamkeitsnachweis eines homoopathischen Salbenpraparats. Fortschr Med. 1988 Feb 20;106(5):96-100.

35. Jaggi R, Wurgler U, Grandjean F, Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxy-genase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004 Apr;53(4):150-7. doi: 10.1007/s00011-003-1236-y. Epub 2004 Mar 18.

36. Lozada C, del Rio E, Reitberg D, et al. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee. Arthritis Rheumatol. 2014;66(S1):266.

37. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a6a2a741-bfd4-4312-817f-e7f4d7bd5a0c